Search results for "liver neoplasm"

showing 10 items of 740 documents

Regulation of cytokinesis and its clinical significance.

2015

Dysregulation of the cell cycle leads to polyploid cells, which are classified into mononuclear or binuclear polyploid cells depending on the number of nuclei. Polyploidy is common in plants and in animals. Physiologically, polyploidy and binucleation are differentiation markers and also features of the aging process. In fact, although they provide multiple copies of genes required for survival, a negative correlation between growth capacity and polyploidy has been reported, and thus, suppression or reversal of this phenomenon may be a growth advantage. On the other hand, unscheduled polyploidization may cause genomic instability that might lead to neoplastic aneuploidy. The aim of this rev…

Genome instabilityClinical BiochemistryBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyMicemedicineAnimalsHumansPI3K/AKT/mTOR pathwayCells CulturedCytokinesisLiver injuryGeneticsMice KnockoutBiochemistry (medical)Cell CycleLiver NeoplasmsCell cyclemedicine.diseaseLiver regenerationCell biologyLiver Regenerationmedicine.anatomical_structureHepatocyteHepatocytesCarcinogenesisCytokinesisCritical reviews in clinical laboratory sciences
researchProduct

Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in li…

2008

Introduction. Long-term steroid administration may predispose liver transplant recipients to infectious and metabolic complication. Maintaining effective immunoprophylaxis while minimizing the negative consequences of steroid therapy could be a key factor in improving clinical outcomes.Methods. Six hundred two patients were randomized to receive tacrolimus (TAC) immunosuppression with a single-steroid bolus and two doses of daclizumab (DAC) or mycophenolate mofetil (MMF).Results. The incidence of biopsy-proven acute rejection was 19.7% in the TAC/DAC group and 16.2% in the TAC/ MMF group (ns). Three-month patient and graft survival were similar. Steroid use at month-3 was low at 5.5% in the…

Graft RejectionLiver CirrhosisMaleDaclizumabmedicine.medical_treatment030230 surgeryLiver transplantationGastroenterology0302 clinical medicineDaclizumabAdrenal Cortex HormonesSafety outcomeAntibacterial agentLiver NeoplasmsAntibodies Monoclonal3. Good healthTreatment OutcomeAcute DiseaseCorticosteroid030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugAdultmedicine.medical_specialtymedicine.drug_classchemical and pharmacologic phenomenaAntibodies Monoclonal HumanizedMycophenolic acidTacrolimusABO Blood-Group System03 medical and health sciencesInternal medicinemedicineHumansTransplantationTacrolimus monotherapybusiness.industryPatient SelectionSteroid-free immunosuppressionMycophenolic AcidSurvival AnalysisTacrolimusSurgeryLiver TransplantationCalcineurinstomatognathic diseasesRegimenImmunoglobulin GbusinessTransplantation
researchProduct

Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: A multicenter European experience

2019

During the last decades, several risk factors for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) have been investigated. However, the impact of two important drivers of oncogenesis, namely the immunosuppression and the treatment of acute cellular rejection (ACR) have been marginally addressed. This study aimed at investigating the impact of ACR treatment on the incidence of tumor recurrence in a large European HCC-LT population. Seven hundred and eighty-one adult patients transplanted between February 1, 1985 and June 30, 2016 were retrospectively analyzed. After propensity score match, 116 patients treated for ACR using steroid boluses were compared with …

Graft RejectionMaleTime Factorsmedicine.medical_treatmentLiver transplantationGastroenterologyAcute rejection; Liver biopsy; Liver transplantation; Recurrence; Steroid0302 clinical medicineRisk FactorsRecurrenceProspective cohort studyeducation.field_of_studymedicine.diagnostic_testIncidenceIncidence (epidemiology)Liver NeoplasmsGastroenterologyImmunosuppressionMiddle AgedLiver biopsyAllograftsEuropeTreatment Outcome030220 oncology & carcinogenesisLiver biopsyHepatocellular carcinomaAcute rejectionFemaleSteroids030211 gastroenterology & hepatologyImmunosuppressive Agentsmedicine.medical_specialtyCarcinoma HepatocellularPopulationRisk Assessment03 medical and health sciencesInternal medicinemedicineHumanseducationSteroidRetrospective StudiesLiver transplantationHepatologybusiness.industrymedicine.diseaseLiver TransplantationTransplantationNeoplasm Recurrence LocalbusinessHepatobiliary & Pancreatic Diseases International
researchProduct

Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein

2008

To evaluate the synergistic targeting and killing of human hepatocellular carcinoma (HCC) cells lacking p53 by the oncolytic autonomous parvovirus (PV) H-1 and chemotherapeutic agents and its dependence on functional promyelocytic leukemia protein (PML).The role of p53 and PML in regulating cytotoxicity and gene transfer mediated by wild-type (wt) PV H-1 were explored in two pairs of isogenic human hepatoma cell lines with different p53 status. Furthermore, H-1 PV infection was combined with cytostatic drug treatment.While the HCC cells with different p53 status studied were all susceptible to H-1 PV-induced apoptosis, the cytotoxicity of H-1 PV was more pronounced in p53-negative than in p…

H-1 parvovirusLiver CancerH-1 parvovirusCarcinoma HepatocellularParvovirus H-1virusesAntineoplastic AgentsApoptosisPromyelocytic Leukemia ProteinPromyelocytic leukemia proteinDrug TherapyCell Line TumorHumansNuclear proteinCytotoxicityMembrane Potential MitochondrialbiologyParvovirusTumor Suppressor ProteinsLiver NeoplasmsGastroenterologyvirus diseasesNuclear ProteinsGeneral Medicinebiology.organism_classificationCombined Modality Therapydigestive system diseasesOncolytic virusApoptosisCancer researchbiology.proteinFluorouracilCisplatinTumor Suppressor Protein p53Transcription FactorsWorld Journal of Gastroenterology
researchProduct

Immunohistochemical Characterization of 130 Cases of Primary Hepatic Carcinomas

1987

Primary liver carcinoma (PLC) may express a certain number of markers. Here we communicate results of an analysis of five such markers (alpha-1-antitrypsin--AAT--, carcino-embryonic antigen --CEA--, alpha-fetoprotein --AFP--, and superficial --HBsAg-- and core --HBcAg-- antigens of hepatitis B virus) by means of PAP techniques in 130 cases of PLC, comparing the neoplastic tissue and the non-tumorous liver. Three variants of PLC are distinguished: hepatocarcinoma (HC) (108 cases); cholangiocarcinoma (CC) (19 cases); and three cases of hepatocholangiocarcinoma (HCC). AAT was positive in 29 HC, 2 HCC, and negative in all 19 CC. CEA appeared positive in 16 HC, 16 CC and only one HCC. AFP was po…

HBsAgPathologymedicine.medical_specialtyCarcinoma HepatocellularCirrhosismedicine.disease_causePathology and Forensic MedicineImmunoenzyme TechniquesAdenoma Bile DuctAntigenCarcinomamedicineHumansneoplasmsTumor markerHepatitis B virusHepatitis B Surface Antigensbusiness.industryLiver NeoplasmsCell Biologymedicine.diseaseHepatitis B Core AntigensImmunohistochemistrydigestive system diseasesCarcinoembryonic AntigenHBcAgalpha 1-AntitrypsinImmunohistochemistryalpha-FetoproteinsbusinessPathology - Research and Practice
researchProduct

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

2018

Abstract Background & Aims Advances in direct‐acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked‐to‐care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030. Methods Using a modelling approach grounded in Italian real‐life data of diagnosed and treated patients, different linkage‐to‐care scenarios were built to evaluate potential strategies in achieving the HCV elimination goals. Results Under the 40% linked‐to‐care scenario, viraemic burden would decline (60%); however, eligible patients to treat w…

HCV; WHO; chronic infection; linkage to careLiver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularSustained Virologic ResponseViral HepatitisSettore MED/12 - GASTROENTEROLOGIAWorld Health OrganizationAntiviral AgentsNO03 medical and health sciencesLiver diseaseWHO0302 clinical medicinePharmacotherapyCost of IllnessCause of DeathHealth caremedicineHumans030212 general & internal medicineViremiachronic infection HCV linkage to care WHODisease EradicationMortalityIntensive care medicineCause of deathlinkage to carechronic infection; HCV; linkage to care; WHODisease EradicationHepatologybusiness.industryPublic healthCarcinomaLiver NeoplasmsHepatocellularHepatitis Cmedicine.diseasechronic infectionHepatitis CMarkov Chainschronic infection; HCV; linkage to care; WHO; Antiviral Agents; Carcinoma Hepatocellular; Cost of Illness; Disease Eradication; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Markov Chains; Mortality; Sustained Virologic Response; Viremia; World Health Organization; Cause of DeathItalychronic infection;HCV;linkage to care;WHOHCVchronic infection; HCV; linkage to care; WHO; Hepatology030211 gastroenterology & hepatologybusinessViral hepatitis
researchProduct

Liver haemangiomas undetermined at grey-scale ultrasound: contrast-enhancement patterns with SonoVue and pulse-inversion US.

2005

The objective of this study was to describe the spectrum of contrast-enhancement patterns of hepatic haemangiomas undetermined at grey-scale ultrasound (US) on SonoVue-enhanced pulse-inversion (PI) US. Twenty patients (11 women, nine men) with 35 haemangiomas (size range: 1-7 cm; mean: 3.1 cm) undetermined at baseline US underwent PI at low M.I. (0.05-0.08) after i.v. injection of SonoVue. All haemangiomas were confirmed by typical helical computed tomography (CT) and/or magnetic resonance imaging (MRI) findings. US examinations were videotaped and then reviewed by two experienced radiologists blinded to the final diagnosis. Readers evaluated by consensus the baseline echogenicity and the d…

HaemangiomaAdultMalemedicine.medical_specialtySulfur HexafluorideContrast MediaHemangiomaLesionUltrasoundmedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyPhospholipidsAgedUltrasonographyNeuroradiologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsUltrasoundEchogenicityMagnetic resonance imagingInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseasebody regionsLiverPulse inversion harmonic imagingFemaleRadiologymedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiaHemangiomabusiness
researchProduct

Imaging of hepatic hemangioma: from A to Z

2019

The hemangioma is the most common solid lesion of the liver. Therefore, radiologists must know the typical and atypical imaging findings of this lesion in order to reach a correct diagnosis and avoid diagnostic errors. However, only few papers have comprehensively described the entire spectrum of atypical and uncommon imaging features. In this updated review, we provide the imaging features of hepatic hemangioma, in both typical and atypical forms, as well as its association with abnormalities in the adjacent hepatic parenchyma and other hepatic lesions, and its complications.

Hepatic Hemangiomamedicine.medical_specialtyUrologyUltrasound (US)Imaging030218 nuclear medicine & medical imagingDiagnosis DifferentialHemangiomaLesion03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingComputed tomography (CT)Radiological and Ultrasound Technologybusiness.industryLiver NeoplasmsGastroenterologyHepatic hemangiomaMagnetic resonance (MR)Hepatologymedicine.diseaseHepatic parenchyma030220 oncology & carcinogenesisRadiologymedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiaHemangiomabusinessAtypicalAbdominal Radiology
researchProduct

Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.

2019

Objective: The HBV HBx regulatory protein is required for transcription from the covalently closed circular DNA (cccDNA) minichromosome and affects the epigenetic control of both viral and host cellular chromatin. Design: We explored, in relevant cellular models of HBV replication, the functional consequences of HBx interaction with DLEU2, a long non-coding RNA (lncRNA) expressed in the liver and increased in human hepatocellular carcinoma (HCC), in the regulation of host target genes and the HBV cccDNA. Results: We show that HBx binds the promoter region, enhances the transcription and induces the accumulation of DLEU2 in infected hepatocytes. We found that nuclear DLEU2 directly binds HBx…

Hepatitis B virusCarcinoma Hepatocellular2312HepatologyvirusesLiver NeoplasmsCell Culture Techniquesmacromolecular substanceshepatocellular carcinomaVirus Replicationliverdigestive system diseasesHepatocytesTrans-ActivatorsHumansEnhancer of Zeste Homolog 2 ProteinRNA Long NoncodingViral Regulatory and Accessory Proteins1506hepatitis BDNA CircularGut
researchProduct

Overexpression of STAT-1 by adenoviral gene transfer does not inhibit hepatitis B virus replication.

2006

Objectives Interferons are known to inhibit the replication of hepatitis B viruses (HBV) in several animal models in vitro and in vivo as well in humans. The STAT-1 protein plays a central role in the biological activity of both type I and type II interferons. The lack of functional STAT-1 renders cells and organisms susceptible to bacterial and viral infectious agents. We analysed whether the overexpression of STAT-1 protein enhances the biological interferon response and whether it elicits antiviral acitivity against HBV in vitro. Methods To achieve an efficient STAT-1 overexpression in primary liver cells and hepatoma cells, we generated a recombinant, replication-deficient adenovirus ex…

Hepatitis B virusCarcinoma HepatocellularBlotting WesternGenetic Vectorsmedicine.disease_causeTransfectionVirus ReplicationVirusHepatitis B virus PRE betaAdenoviridaeOrthohepadnavirusInterferonmedicineTumor Cells CulturedAnimalsHumansCells CulturedHepatitis B virusHepatologybiologyLiver NeoplasmsGastroenterologyvirus diseasesHepatitis Bmedicine.diseasebiology.organism_classificationVirologyMolecular biologydigestive system diseasesIn vitroDucksSTAT1 Transcription FactorHepadnaviridaeGene Expression RegulationDNA ViralHepatocytesmedicine.drugEuropean journal of gastroenterologyhepatology
researchProduct